KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV)
Health Care · Biotechnology · US
$—
— today · — 1Y
KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) operates in the Biotechnology industry within the Health Care sector.
trading between 10.41 and 27.00.
Tweenvest scores KalVista Pharmaceuticals, Inc. across four factors: quality 24/100, value 84/100. Its strongest factor is value.
KALV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $114.48M
- P/E
- —
- EPS
- -2.51
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $27.00
- 52-week low
- $10.41
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 275
- Next earnings
- —
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.
- ISIN
- US4834971032
- Listed since
- Apr 9, 2015
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.